John M. Wallmark

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

Aaron R. Hansen, Christophe Massard, Patrick A. Ott et al. · Annals of Oncology · 2018 · 367 citations

Pharmacy, Oncology, Pharmacotherapy +17

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

Bert H. O’Neil, John M. Wallmark, David Lorente et al. · PLoS ONE · 2017 · 305 citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma

Roger B. Cohen, Jean‐Pierre Delord, Toshihiko Doi et al. · American Journal of Clinical Oncology · 2018 · 206 citations · Full text

Medicine, Oncology, Pharmacology +16

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

Joyce O’Shaughnessy, Susana Sousa, Josefina Cruz et al. · European Journal of Cancer · 2021 · 74 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study

Aaron R. Hansen, Christophe Massard, P.A. Ott et al. · Annals of Oncology · 2016 · 48 citations · Full text

Medicine, Oncology, Urology +13